Clinical Trials
4,103 trialsNCT00600496 2026-05-27
A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)
AstraZeneca
Phase 1 Completed
NCT06619873 2026-05-27
A Clinical Study to Evaluate the Relative Bioavailability and Food Effect of HRS-8080 in Healthy Subjects
Shandong Suncadia Medicine Co., Ltd.
Phase 1 Completed
NCT04846920 2026-05-22
MK-6482-018
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT05534620 2026-05-20
Effect of Moderate Renal Impairment and Race/Ethnicity on Treosulfan Pharmacokinetics
medac GmbH
Phase 1 Completed
NCT00629759 2026-05-19
A Study of Recombinant Vaccinia Virus to Evaluate the Safety and Efficacy of a Transdermal Injection Within the Tumor of Patients With Primary or Metastatic Hepatic Carcinoma
SillaJen, Inc.
Phase 1 Completed
NCT04130542 2026-05-19
Phase 1 Trial of LVGN6051 as Single Agent and in Combination With Keytruda (Pembrolizumab) in Advanced or Metastatic Malignancy
Lyvgen Biopharma Holdings Limited
Phase 1 Completed
NCT04635995 2026-05-19
Phase 1 Trial of LVGN7409 (CD40 Agonist Antibody) as Single Agent and Combination Therapies in Advanced or Metastatic Malignancy
Lyvgen Biopharma Holdings Limited
Phase 1 Completed
NCT06713564 2026-05-19
A Single Dose, Open-Label, Dose-escalation Study of the Safety and Imaging Characteristics of LS301-IT for Intraoperative Imaging of Lung Cancer
Integro Theranostics
Phase 1 Completed
NCT07454863 2026-05-14
A Mass Balance Study of DZD8586 in Healthy Male Participants (TAI-SHAN15)
Dizal Pharmaceuticals
Phase 1 Completed
NCT02797795 2026-05-13
A Phase 1, Open-Label, Dose-Escalation Study of NEV801, Administered to Patients With Advanced Cancers
Neovia Oncology Ltd.
Phase 1 Completed
NCT04093596 2026-05-13
UNIVERSAL
Allogene Therapeutics
Phase 1 Completed
NCT05673460 2026-05-13
MK-1026-002
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT06649006 2026-05-13
Study to Investigate Intravenous Blinatumomab in Japanese Adult Participants With Newly Diagnosed Philadelphia-negative B-precursor Acute Lymphoblastic Leukemia (B-ALL)
Amgen
Phase 1 Completed
NCT03017807 2026-05-12
Safety and Pharmacokinetics of Recombinant Anti-EGFr Antibody in Patients With Metastatic Colorectal Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 1 Completed
NCT04354246 2026-05-12
COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies
Compugen Ltd
Phase 1 Completed
NCT04619056 2026-05-12
First-in-man Clinical Trial of CEB-01 PLGA Membrane in Recurrent or Locally Advanced Retroperitoneal Soft Tissue Sarcoma
CEBIOTEX
Phase 1 Completed
NCT05162755 2026-05-12
S095029 as Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies Followed by an Expansion Part With Triple Combinations in Patients With Metastatic Gastric or Colorectal Cancers
Servier
Phase 1 Completed
NCT01905813 2026-05-11
Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies
Incyte Corporation
Phase 1 Completed
NCT05076396 2026-05-11
PM14 Administered Intravenously to Patients With Advanced Solid Tumors
PharmaMar
Phase 1 Completed
NCT05919069 2026-05-11
A Phase I Study to Investigate the Effect of Hepatic Impairment on the PK, Safety, and Tolerability of AZD2693
AstraZeneca
Phase 1 Completed
NCT05387928 2026-05-08
A Study of KL340399 in Patients With Advanced Solid Tumors
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 1 Completed
NCT05549804 2026-05-08
A Study of Intratumoral KL340399 in Patients With Advanced Solid Tumors
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 1 Completed
NCT03552718 2026-05-07
QUILT-2.025 NANT Neoepitope Yeast Vaccine (YE-NEO-001): Adjuvant Immunotherapy Using a Personalized Neoepitope Yeast-Based Vaccine To Induce T-Cell Responses In Subjects W/ Previously Treated Cancers.
NantBioScience, Inc.
Phase 1 Completed
NCT05155709 2026-05-07
A Study of Siremadlin in Combination With Venetoclax Plus Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Chemotherapy.
Novartis
Phase 1 Completed
NCT06091930 2026-05-07
A Study to Test Different Doses of BI 765049 Alone and in Combination With Ezabenlimab in Asian People With Advanced Cancer (Solid Tumours) Positive for B7-H6
Boehringer Ingelheim
Phase 1 Completed
NCT04380753 2026-05-06
AMG 510 Ethnic Sensitivity Study (CodeBreaK 105).
Amgen
Phase 1 Completed
NCT05829226 2026-05-06
A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)
PureTech
Phase 1 Completed
NCT04457778 2026-05-04
First in Human Study of M6223
EMD Serono
Phase 1 Completed
NCT05824663 2026-05-04
A Study Evaluating the Safety, Tolerance and Anti-tumor Activity of HBM1020 in Subjects With Advanced Solid Tumors
Harbour BioMed US, Inc.
Phase 1 Completed
NCT04819854 2026-04-29
Single and Multiple Ascending Dose Study With EP395
EpiEndo Pharmaceuticals
Phase 1 Completed
NCT05177042 2026-04-28
Trial of ARV-110 and Abiraterone in Participants With Metastatic Prostate Cancer
Arvinas Inc.
Phase 1 Completed
NCT07554196 2026-04-28
A Phase 1 Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HH-101 in Patients With Advanced Solid Tumors
Huahui Health
Phase 1 Completed
NCT05085548 2026-04-27
ProAgio in Previously Treated Advanced Pancreatic Cancer and Other Solid Tumor Malignancies
ProDa BioTech, LLC
Phase 1 Completed
NCT06104449 2026-04-27
MK-5684-005
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT06308263 2026-04-23
Tuvusertib (M1774) Human Mass Balance and Absolute Bioavailability Study (DDRIVER Solid Tumors 303)
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Phase 1 Completed
NCT05376527 2026-04-21
Open Multi-cohort Study of the First Phase of Safety of a Drug Based on Double Recombinant Vaccinia Virus VV-GMCSF-Lact
"Oncostar" LLC
Phase 1 Completed
NCT07450833 2026-04-20
BOOST
Benfovir AG
Phase 1 Completed
NCT03317743 2026-04-17
Study to Assess the Safety & Tolerability of NOV140101(IDX-1197) in Patients With Advanced Solid Tumors
Idience Co., Ltd.
Phase 1 Completed
NCT03732768 2026-04-17
Study of Radspherin® in Recurrent Ovarian Cancer Subjects With Peritoneal Carcinomatosis
Oncoinvent Solutions AS
Phase 1 Completed
NCT03881488 2026-04-17
Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
Compass Therapeutics
Phase 1 Completed
NCT05022849 2026-04-17
A Study of JNJ-75229414 for Metastatic Castration-resistant Prostate Cancer Participants
Janssen Research & Development, LLC
Phase 1 Completed
NCT06929195 2026-04-14
Clinical Trial to Evaluate the Tolerance of TQB2210 Injection
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Completed
NCT04557150 2026-04-13
A Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of Forimtamig in Participants With Relapsed or Refractory Multiple Myeloma (r/r MM)
Hoffmann-La Roche
Phase 1 Completed
NCT03850873 2026-04-09
A Phase I Study of TQB3616 on Tolerance and Pharmacokinetics
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Completed
NCT03984097 2026-04-09
A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)
Takeda
Phase 1 Completed
NCT04049825 2026-04-08
A Phase 1 Trial of OPB-111077 in Combination With Bendamustine and Rituximab in Patients With r/r DLBCL
Otsuka Pharmaceutical Co., Ltd.
Phase 1 Completed
NCT04833582 2026-04-03
A Study of Azenosertib (ZN-c3) in Combination With Gemcitabine in Subjects With Osteosarcoma
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Phase 1 Completed
NCT07160738 2026-04-03
A Study to Learn About How the Study Medicines Called Itraconazole and Probenecid Change How the Body Processes PF-07220060
Pfizer
Phase 1 Completed
NCT07497373 2026-04-03
JL15003
Jecho Biopharmaceuticals Co., Ltd.
Phase 1 Completed
NCT03798626 2026-04-01
Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers
Novartis
Phase 1 Completed